

# Uptake of Triiodothyronine Sulfate and Suppression of Thyrotropin Secretion in Cultured Anterior Pituitary Cells

M.E. Everts, T.J. Visser, J.C.J. van Buuren, R. Docter, M. de Jong, E.P. Krenning, and G. Hennemann

To investigate the uptake of triiodothyronine sulfate ( $T_3S$ ) and its effect on thyrotropin-releasing hormone (TRH)-induced thyrotropin (TSH) secretion, anterior pituitary cells were isolated from euthyroid rats and cultured for 3 days in medium containing 10% fetal calf serum. Incubation was performed at 37°C in medium containing 0.5% bovine serum albumin (BSA). Exposure of the pituitary cells to TRH (0.1  $\mu\text{mol/L}$ ) for 2 hours stimulated TSH secretion by 176%. This effect was reduced by approximately 45% after a 2-hour preincubation with  $T_3$  (0.001 to 1  $\mu\text{mol/L}$ ). A significant inhibitory effect of  $T_3S$  on TRH-induced TSH release was only observed at a concentration of 1  $\mu\text{mol/L}$ . The uptake of [ $^{125}\text{I}$ ] $T_3$  after 1 hour of incubation was reduced by 40%  $\pm$  4% ( $P < .001$ ) by simultaneous addition of 10 nmol/L unlabeled  $T_3$ , whereas 1  $\mu\text{mol/L}$   $T_3S$  was required to obtain a reduction of the [ $^{125}\text{I}$ ] $T_3$  uptake by 34%  $\pm$  2% ( $P < .001$ ). The amount of  $T_3$  present in the unlabeled  $T_3S$  preparation was 0.25% as determined by radioimmunoassay. When pituitary cells were incubated for 1 hour with [ $^{125}\text{I}$ ] $T_3S$  or [ $^{125}\text{I}$ ] $T_3$  (both 50,000 cpm/0.25 mL), the uptake of [ $^{125}\text{I}$ ] $T_3S$  expressed as a percentage of the dose was 0.04%  $\pm$  0.02% (mean  $\pm$  SE,  $n = 4$ ), whereas that of [ $^{125}\text{I}$ ] $T_3$  amounted to 3.0%  $\pm$  0.4% ( $n = 4$ ). In contrast, when hepatocytes were incubated for 1 hour with [ $^{125}\text{I}$ ] $T_3S$ , the uptake amounted to 5.1%  $\pm$  0.8% ( $n = 9$ ), whereas that of [ $^{125}\text{I}$ ] $T_3$  was 22.1%  $\pm$  1.7% ( $n = 9$ ). Furthermore, [ $^{125}\text{I}$ ] $T_3S$  was as rapidly deiodinated (iodide production, 14.9%  $\pm$  2.6%;  $n = 9$ ) as [ $^{125}\text{I}$ ] $T_3$  (12.1%  $\pm$  0.8%,  $n = 9$ ) by hepatocytes. It is concluded that (1)  $T_3S$  is poorly taken up by pituitary cells, and (2) the suppressive effect of high concentrations of  $T_3S$  on TRH-induced TSH secretion and on [ $^{125}\text{I}$ ] $T_3$  uptake can be explained by slight contamination with  $T_3$ . Thus, it appears that  $T_3S$  has only a minor biological effect, if any, on the pituitary.

Copyright © 1994 by W.B. Saunders Company

**S**ULFATION plays a significant role in the metabolism of iodothyronines in both man and animals, although it is probably more important for triiodothyronine ( $T_3$ ) than for thyroxine, at least in rats and dogs.<sup>1-3</sup> However, during nonthyroidal illness (NTI) the contribution of the different pathways, ie, deiodination, glucuronidation, and sulfation, to thyroid hormone metabolism might change considerably.<sup>4,5</sup> Measurements of the hormone levels in sera of NTI patients showed that the reduction in serum  $T_3$  and thyroxine was accompanied by a threefold increase in serum  $T_3$  sulfate ( $T_3S$ ) apart from the known increase in serum reverse  $T_3$ .<sup>6</sup> Despite these changes, serum thyrotropin (TSH) was in the normal range.<sup>6</sup>

In the study by LoPresti et al,<sup>7</sup> the question was raised as to whether the increased  $T_3S$  production might contribute to the suppression of TSH secretion during NTI. In their experiments, infusion of  $T_3S$  in healthy volunteers, calculated to result in a relatively low serum level of  $T_3S$ , did not reduce the serum TSH level.<sup>7</sup> In another study with the growth hormone-producing pituitary tumor cell line GH<sub>4</sub>C<sub>1</sub>, it was shown that  $T_3S$  failed to displace [ $^{125}\text{I}$ ] $T_3$  from the nuclear binding sites.<sup>8</sup> However, the possibility that  $T_3S$  could have thyromimetic activity after desulfation was not excluded.<sup>8,9</sup> More recently, it was reported that administration of  $T_3S$  to hypothyroid rats produced thyromimetic

effects with a potency of approximately 20% that of  $T_3$ .<sup>10</sup> In the same study, it was shown that treatment of hypothyroid rats with a relatively high dose of  $T_3S$  resulted in a reduction of serum TSH and a normalization of the serum  $T_3$  level, indicating desulfation of  $T_3S$  in vivo.<sup>10</sup>

Together, these results could be explained by the assumption that  $T_3S$  is not taken up by the pituitary, and that the effects of  $T_3S$  in vivo might be due to an effect of  $T_3$  (after desulfation or due to contamination of  $T_3S$ ). To test this hypothesis, the present study was undertaken to examine in vitro the effects of  $T_3S$  on TSH secretion and the uptake of [ $^{125}\text{I}$ ] $T_3S$  by the pituitary. We used primary cultures of anterior pituitary cells of euthyroid rats. This preparation contains active thyrotrophs that release TSH in response to (TSH-releasing hormone [TRH]) and transport  $T_3$  by a carrier-mediated mechanism.<sup>11</sup> Since it is not known whether  $T_3S$  is metabolized in the pituitary like it is in the liver<sup>12</sup> and whether possible effects of  $T_3S$  on pituitary function should be ascribed to  $T_3S$  itself or to any metabolic product, we have also compared pituitary cells and hepatocytes with respect to the uptake and deiodination of [ $^{125}\text{I}$ ] $T_3S$  and [ $^{125}\text{I}$ ] $T_3$ .

## MATERIALS AND METHODS

### Animals

All experiments were performed using male Wistar rats weighing 220 to 250 g. The animals had free access to food and water and were kept in a controlled environment (21°C) with constant day length (12 hours).

### Pituitary Cell Culture

Animals (12 for each experiment) were killed between 9:00 and 9:30 AM by decapitation. The pituitary glands were removed within 5 minutes, the neurointermediate lobe was discarded, and the anterior lobes were collected in calcium- and magnesium-free Hanks balanced salt solution supplemented with 10 g/L human serum albumin, penicillin (10<sup>5</sup> U/L), amphotericin B (Fungizone,

From the Departments of Internal and Nuclear Medicine, Erasmus University Medical School, Rotterdam, The Netherlands.

Submitted August 5, 1993; accepted December 16, 1993.

Supported by the Trustfonds of the Erasmus University Rotterdam, The Netherlands. M.E.E. holds a fellowship from the Royal Netherlands Academy of Arts and Sciences.

Address reprint requests to M.E. Everts, PhD, Department of Internal Medicine III, Erasmus University Medical School, Postbox 1738, NL-3000 DR Rotterdam, The Netherlands.

Copyright © 1994 by W.B. Saunders Company

0026-0495/94/14310-0013\$03.00/0

Bristol-Myers Squibb, Woerden, The Netherlands; 0.5 mg/L), and sodium bicarbonate (0.4 g/L). The anterior pituitary lobes were dissociated with dispase ( $2.4 \times 10^3$  U/L) as described in detail elsewhere.<sup>13</sup> From each pituitary, 1 to  $1.5 \times 10^6$  cells were obtained, and the viability of the cells as determined by trypan blue exclusion was greater than 90%.

The cells were cultured at 37°C in a water-jacketed incubator in humidified air with 5% CO<sub>2</sub> at a density of 3 to  $5 \times 10^5$  cells per well in 48-well culture dishes. The culture medium consisted of Minimal Essential Medium with Earle's salts supplemented with nonessential amino acids, sodium pyruvate (1 mmol/L), 10% fetal calf serum, penicillin ( $10^5$  U/L), amphotericin B (0.5 mg/L), L-glutamine (2 mmol/L), and sodium bicarbonate (2.2 g/L, pH 7.4).<sup>13,14</sup> The cells had attached to the wells after 2 days of culture; on day 3, the cells were used for experiments. In a previous study it was shown that the TSH content of the pituitary cell preparation was highest after this short period of culture.<sup>11</sup>

#### TSH Secretion

The culture medium was removed from the cells, and the cells were washed once with incubation medium. This medium was identical to the culture medium except that the fetal calf serum was replaced by 0.5% bovine serum albumin (BSA). The pituitary cells were preincubated for 2 hours at 37°C in the absence or presence of variable concentrations of T<sub>3</sub> or T<sub>3</sub>S (0.001 to 1 μmol/L). The medium was then discarded, and fresh medium was added containing TRH (0.1 μmol/L) with or without T<sub>3</sub> or T<sub>3</sub>S. Incubation was continued for 2 hours at 37°C and was followed by removal of the medium. The cells were washed once with 1 mL ice-cold saline (0.9% NaCl). Incubation media were centrifuged ( $2,000 \times g$ ), and the supernatants were frozen for later determination of TSH. Incubations were performed in triplicate.

#### Hepatocytes

Hepatocytes were isolated by collagenase perfusion as previously described.<sup>15</sup> Cells were cultured at 37°C at a density of  $2 \times 10^6$  cells per well in 6-well culture dishes in 2 mL Ham's F10, HEPES (8.9 mmol/L), PIPES (10.6 mmol/L), and *N,N*-bis[2-hydroxyethyl]-2-aminoethane sulfonic acid ([BES] 11.2 mmol/L) supplemented with 10% fetal calf serum, CaCl<sub>2</sub> (2 mmol/L), glucose (6.7 mmol/L), insulin (12 U/L), and penicillin/streptomycin ( $5 \times 10^4$  U/L, pH 7.4). After 4 hours of culture, the cells were washed once with rinsing medium and used for experiments.<sup>16</sup>

#### Uptake of [<sup>125</sup>I]T<sub>3</sub> and [<sup>125</sup>I]T<sub>3</sub>S

For these studies, cells were cultured as described above. On the same culture dishes, an equal number of wells contained only culture medium (blanks). All incubations with and without cells were performed in triplicate.

Pituitary cells were equilibrated in 0.5 mL culture medium containing 0.5% BSA. After equilibration for 30 minutes, the medium was removed and the cells were incubated for 1 hour at 37°C with [<sup>125</sup>I]T<sub>3</sub> (50,000 cpm, 50 pmol/L) in 0.25 mL medium alone or together with 0.01 to 10 μmol/L T<sub>3</sub> or T<sub>3</sub>S. The uptake of [<sup>125</sup>I]T<sub>3</sub>S (50,000 cpm) was measured exactly as for [<sup>125</sup>I]T<sub>3</sub>.

To allow direct comparison with the hepatocyte experiments, two experiments with pituitary cells were performed in incubation medium where NaHCO<sub>3</sub> was replaced by an equimolar amount of HEPES (8.9 mmol/L), PIPES (10.6 mmol/L), and BES (11.2 mmol/L). As previously described, this did not affect the uptake of [<sup>125</sup>I]T<sub>3</sub> by the pituitary cells<sup>11</sup> (Table 2).

After incubation, the medium was removed and the cells were washed with 1 mL ice-cold saline to remove labeled compounds not bound to the cells. Cells were dissolved in 1 mL 0.1N NaOH and

were counted for radioactivity in a 16-channel gamma counter (NE 1600, Nuclear Enterprises, Sighthill, Edinburgh, Scotland). The amount of [<sup>125</sup>I]T<sub>3</sub> or [<sup>125</sup>I]T<sub>3</sub>S taken up by the cells was expressed as a percentage of the dose. The same procedure was applied to the incubations without cells. All results are corrected for the amount of radioactivity retained in the wells without cells.

Hepatocytes were incubated with [<sup>125</sup>I]T<sub>3</sub> or [<sup>125</sup>I]T<sub>3</sub>S (both 100,000 cpm/mL) at 37°C for 1 to 120 minutes in 1 mL hepatocyte culture medium with 0.5% BSA instead of fetal calf serum. Further processing was the same as for pituitary cells.

#### Iodide Production

Aliquots of the incubation medium from the three uptake experiments with hepatocytes (Fig 2) and the two experiments with pituitary cells (Table 2) were chromatographed on Sephadex LH-20.<sup>16</sup> Iodide was eluted from the column with  $3 \times 1$  mL 0.1N HCl. Subsequently, glucuronides and sulfates (conjugates) were eluted with  $8 \times 1$  mL H<sub>2</sub>O, and finally the iodothyronines were removed from the column with  $3 \times 1$  mL 50% ethanol in 0.1N NaOH.

#### Determination of TSH

TSH levels in the incubation media were measured by radioimmunoassay as previously described.<sup>11</sup>

#### Analysis of T<sub>3</sub>S

The purity of the unlabeled T<sub>3</sub>S preparation was tested by conventional radioimmunoassay with two T<sub>3</sub> antisera produced in our laboratory (no. 7157 and 7160). Both antisera were used in a final dilution of 1:200,000.

#### Free T<sub>3</sub> and T<sub>3</sub>S Concentrations

Calculation of the free T<sub>3</sub> and T<sub>3</sub>S concentrations in the experiments was based on the determination of the free fractions by equilibrium dialysis.<sup>17</sup> With 0.5% BSA in the incubation medium, the free T<sub>3</sub> fraction amounted to  $2.85\% \pm 0.01\%$  ( $n = 4$ ), and the free T<sub>3</sub>S fraction to  $2.12\%$  ( $n = 2$ ). The free T<sub>3</sub>S fraction was corrected for the fact that only 60% of the T<sub>3</sub>S precipitated with MgCl<sub>2</sub>. It was further checked by high-performance liquid chromatography that this was not due to the presence of iodide in the [<sup>125</sup>I]T<sub>3</sub>S preparation.

#### Materials

All solutions used for cell isolation and cell culture were obtained from GIBCO Europe (Breda, The Netherlands), with the exception of human serum albumin (Rhône-Poulenc, Amstelveen, The Netherlands), dispase (grade II, Boehringer, Mannheim, Germany), and collagenase (type I, Sigma, St Louis, MO). Culture dishes (48- and 6-well) were purchased from Costar (Cambridge, MA) and Nunc (Roskilde, Denmark), respectively. TRH (Relefact) was obtained from Hoechst, Frankfurt am Main, Germany. T<sub>3</sub>, PIPES, HEPES, BES, and BSA (fraction V) were purchased from Sigma (St Louis, MO). [<sup>3</sup>H-<sup>125</sup>I]T<sub>3</sub> (3,070 μCi/μg) was purchased from Amersham International (Aylesbury, Buckinghamshire, UK). T<sub>3</sub>S and [<sup>125</sup>I]T<sub>3</sub>S were prepared from T<sub>3</sub> and [<sup>125</sup>I]T<sub>3</sub>, respectively, using ClSO<sub>3</sub>H.<sup>18</sup> [<sup>125</sup>I]T<sub>3</sub>S was purified by LH-20 chromatography, and analysis of the fractions by high-performance liquid chromatography<sup>18</sup> showed that the preparation consisted of 98% T<sub>3</sub>S and contained less than 2% iodide. Reagents for the rat TSH radioimmunoassay were kindly provided by the National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, MD). Sephadex G25 was obtained from Pharmacia (Uppsala, Sweden). All other reagents were of the highest purity available.

### Statistics

Significances of differences were calculated with Student's *t* test for unpaired observations. A *P* value less than .05 was regarded as statistically significant.

## RESULTS

### Effects of T<sub>3</sub>S on TSH Secretion

Table 1 shows a comparison of the effects of various concentrations of T<sub>3</sub> and T<sub>3</sub>S on the TRH-induced TSH secretion by anterior pituitary cells. When TRH was added at a concentration of 0.1 μmol/L, TSH release was stimulated by 176% (*P* < .001). This effect was reduced by approximately 45% after preincubation with 1 μmol/L T<sub>3</sub> or T<sub>3</sub>S (*P* < .001 for both). The inhibitory effect of T<sub>3</sub> on TRH-induced TSH secretion was the same after preincubation with lower concentrations of T<sub>3</sub> (0.1 and 0.01 μmol/L). In contrast, the effect of preincubation with 0.1 μmol/L T<sub>3</sub>S was much smaller (14%, NS), and at 0.01 μmol/L T<sub>3</sub>S the effect was completely absent. An additional experiment was performed where the effects of even lower concentrations of T<sub>3</sub> and T<sub>3</sub>S on TRH-induced TSH secretion were compared. TRH-induced TSH release was inhibited by 62% (*P* < .025 or less) at T<sub>3</sub> concentrations of 0.01, 0.1, and 1.0 μmol/L, and by 41% (.05 < *P* < .10) at a T<sub>3</sub> concentration of 0.001 μmol/L. The effect of T<sub>3</sub>S was absent at 0.001 and 0.01 μmol/L, and the maximum effect was obtained at a concentration of 1 μmol/L T<sub>3</sub>S and amounted to 53% (*P* < .025).

### Effects of T<sub>3</sub>S on [<sup>125</sup>I]T<sub>3</sub> Uptake


A comparison between the effects of T<sub>3</sub> and T<sub>3</sub>S was also made with respect to the uptake of [<sup>125</sup>I]T<sub>3</sub> by the pituitary cells. Figure 1 shows the combined results of three experiments. In the first experiment with 300,000 cells per well the control uptake of [<sup>125</sup>I]T<sub>3</sub> was 1.62% ± 0.03% (*n* = 3), and in the second and third experiments with 500,000 cells per well it was 3.96% ± 0.15% (*n* = 3) and 2.39% ± 0.08% (*n* = 5). Simultaneous incubation of the cells with 0.01, 0.1, 1, and 10 μmol/L unlabeled T<sub>3</sub> reduced the uptake of

**Table 1. Effects of T<sub>3</sub> and T<sub>3</sub>S on the TRH-Induced Stimulation of TSH Release From Anterior Pituitary Cells**

Experimental Conditions	TSH Release (ng)	Effect (%)	<i>P</i>
Controls (14)	2.1 ± 0.1		
+TRH 0.1 μmol/L (14)	5.8 ± 0.2	+176	<.001
TRH + T <sub>3</sub> 1 μmol/L (8)	4.1 ± 0.3	+95	<.001*
TRH + T <sub>3</sub> S 1 μmol/L (9)	3.9 ± 0.3	+86	<.001*
TRH + T <sub>3</sub> 0.1 μmol/L (3)	4.3 ± 0.1	+104	<.025*
TRH + T <sub>3</sub> S 0.1 μmol/L (6)	5.3 ± 0.2	+152	NS*
TRH + T <sub>3</sub> 0.01 μmol/L (6)	4.2 ± 0.2	+100	<.001*
TRH + T <sub>3</sub> S 0.01 μmol/L (6)	5.7 ± 0.1	+171	NS*

NOTE. Data are the mean ± SE of three independent experiments, with the number of observations in parentheses. Anterior pituitary cells were cultured for 3 days at a density of 5 × 10<sup>5</sup> cells/well. The cells were preincubated for 2 hours in the absence or presence of T<sub>3</sub> (0.01 to 1 μmol/L) or T<sub>3</sub>S (0.01 to 1 μmol/L). Then they were incubated with TRH (0.1 μmol/L) for 2 hours with or without the additions indicated.

\**P* values calculated compared with the addition of TRH alone.



**Fig 1. Effects of unlabeled (○) T<sub>3</sub> and (●) T<sub>3</sub>S on the uptake of [<sup>125</sup>I]T<sub>3</sub> by anterior pituitary cells. The cells were cultured for 3 days at a density of 3 to 5 × 10<sup>5</sup> cells/well. After equilibration, the cells were incubated for 1 hour with [<sup>125</sup>I]T<sub>3</sub> (50,000 cpm) with various concentrations of unlabeled T<sub>3</sub> or T<sub>3</sub>S. Data represent the mean ± SE of three to nine observations from three independent experiments. Significances of differences were calculated as compared with the controls (100%): \**P* < .025, \*\**P* < .001.**

[<sup>125</sup>I]T<sub>3</sub> by 40% ± 4% (*P* < .001), 40% ± 5% (*P* < .001), 52% ± 2% (*P* < .001), and 56% ± 1% (*P* < .001), respectively. When T<sub>3</sub>S was added at concentrations of 0.01, 0.1, 1, or 10 μmol/L, [<sup>125</sup>I]T<sub>3</sub> uptake was reduced by 6% ± 4% (NS), 11% ± 4% (*P* < .025), 34% ± 2% (*P* < .001), and 52% ± 5% (*P* < .001), respectively.


### Uptake of [<sup>125</sup>I]T<sub>3</sub>S by Pituitary Cells and Hepatocytes

In four experiments with 500,000 cells per well, the uptake of [<sup>125</sup>I]T<sub>3</sub>S by pituitary cells was compared with that of [<sup>125</sup>I]T<sub>3</sub> (Table 2). After 1 hour of incubation the uptake of [<sup>125</sup>I]T<sub>3</sub>S was less than 0.1%, whereas the mean uptake of [<sup>125</sup>I]T<sub>3</sub> amounted to 3.0% ± 0.4% (Table 2). In contrast, both [<sup>125</sup>I]T<sub>3</sub>S and [<sup>125</sup>I]T<sub>3</sub> were taken up by hepatocytes (Fig 2A), although the uptake of [<sup>125</sup>I]T<sub>3</sub> was roughly fourfold greater than that of [<sup>125</sup>I]T<sub>3</sub>S. The uptake of both compounds reached a maximum value between 0.5 and 1 hour of incubation, and then declined slightly. As can be seen from Fig 2B, both T<sub>3</sub> and T<sub>3</sub>S were deiodinated in hepatocytes, and iodide production from [<sup>125</sup>I]T<sub>3</sub>S was at

**Table 2. Comparison of the Uptake of [<sup>125</sup>I]T<sub>3</sub> and [<sup>125</sup>I]T<sub>3</sub>S in Anterior Pituitary Cells**

Experiment No.	[ <sup>125</sup> I]T <sub>3</sub> Uptake (% dose)	[ <sup>125</sup> I]T <sub>3</sub> S Uptake (% dose)
1	2.96 ± 0.02	0.01 ± 0.04
2	2.64 ± 0.09	0.07 ± 0.02
3	2.34 ± 0.13	0.00 ± 0.05
4	3.96 ± 0.15	0.09 ± 0.06

NOTE. Data represent the mean ± SE of triplicate determinations. Anterior pituitary cells were cultured for 3 days at a density of 5 × 10<sup>5</sup> cells/well. Experiments 1 and 2 were performed in incubation medium containing NaHCO<sub>3</sub>, and experiments 3 and 4 in incubation medium containing HEPES, BES, and PIPES. The cells were equilibrated for 30 minutes in incubation medium and then incubated for 1 hour with [<sup>125</sup>I]T<sub>3</sub> or [<sup>125</sup>I]T<sub>3</sub>S (both 50,000 cpm/0.25 mL).



**Fig 2.** Time course of the (A) uptake of (○) [<sup>125</sup>I]T<sub>3</sub> and (●) [<sup>125</sup>I]T<sub>3</sub>S and (B) iodide production by primary cultures of hepatocytes. Hepatocytes were incubated for periods varying from 1 minute to 2 hours with [<sup>125</sup>I]T<sub>3</sub> or [<sup>125</sup>I]T<sub>3</sub>S (both 100,000 cpm/mL). Iodide production after 1 and 2 hours of incubation was measured in the media by LH-20 chromatography. Data represent the mean ± SE of nine observations from three independent experiments. (□) Iodide production from [<sup>125</sup>I]T<sub>3</sub>; (■) iodide production from [<sup>125</sup>I]T<sub>3</sub>S.

least as high as that from [<sup>125</sup>I]T<sub>3</sub>. Furthermore, iodide production from T<sub>3</sub> and T<sub>3</sub>S doubled when the incubation time was prolonged from 1 to 2 hours. In the same 1-hour period, the mean conjugate formation from [<sup>125</sup>I]T<sub>3</sub> was 4.7% ± 0.8% (not shown). There was no production of unconjugated T<sub>3</sub> from [<sup>125</sup>I]T<sub>3</sub>S by hepatocytes during the course of the experiment (not shown).

To determine if pituitary cells also metabolized T<sub>3</sub> and T<sub>3</sub>S, incubation media from the last two experiments shown in Table 2 were analyzed for iodide production. Neither in the media from the pituitary cells incubated with [<sup>125</sup>I]T<sub>3</sub> nor in those from [<sup>125</sup>I]T<sub>3</sub>S incubations was iodide detectable. After incubation with [<sup>125</sup>I]T<sub>3</sub>, no conjugates were detected, and 95% of the radioactivity appeared in the iodothyronine fraction. In the case of [<sup>125</sup>I]T<sub>3</sub>S, 90% to 95% of the radioactivity was found in the conjugate fraction, and no radioactivity was found in the iodothyronine fraction (not shown).

#### Purity of Unlabeled T<sub>3</sub>S

Finally, the amount of T<sub>3</sub> present in the unlabeled T<sub>3</sub>S preparation was determined by radioimmunoassay with two

different antisera, showing that the T<sub>3</sub>S preparation contained 0.25% T<sub>3</sub>. Incubation medium with 1 μmol/L T<sub>3</sub>S contained 2.49 nmol/L T<sub>3</sub> before incubation with cells and 2.08 ± 0.02 (n = 3) nmol/L T<sub>3</sub> after incubation with cells.

#### DISCUSSION

The results of the present study indicate that T<sub>3</sub>S does not play a significant role in the suppression of TSH secretion in pituitary cells *in vitro*. Furthermore, our results suggest essential differences in the metabolic handling of T<sub>3</sub> and T<sub>3</sub>S by pituitary cells and hepatocytes.

LoPresti et al<sup>7</sup> suggested that T<sub>3</sub>S might play a role in the suppression of TSH secretion during NTL. This hypothesis seemed already somewhat weakened by their own observation that infusion of T<sub>3</sub>S in healthy volunteers did not result in decreased levels of serum TSH. On the other hand, the serum level of T<sub>3</sub>S achieved during the infusion was not measured, and the lack of effect of T<sub>3</sub>S could be due to the low calculated T<sub>3</sub>S/T<sub>3</sub> ratio (46%).

Although 1 μmol/L T<sub>3</sub>S was as effective as 1 μmol/L T<sub>3</sub> in suppressing the TRH-induced TSH secretion in our cell culture, this effect can simply be explained on the basis of a slight contamination of the T<sub>3</sub>S preparation with T<sub>3</sub>. The amount of T<sub>3</sub> in the unlabeled T<sub>3</sub>S preparation was 0.25%, and hence, 1 μmol/L T<sub>3</sub>S will roughly contain 2.5 nmol/L T<sub>3</sub>. This idea was confirmed by the experiment where the effect of 1 μmol/L T<sub>3</sub>S on TRH-induced TSH secretion was found to correspond to a value (53%) just between 1 nmol/L T<sub>3</sub> (41%) and 10 nmol/L T<sub>3</sub> (62%).

The effect of unlabeled T<sub>3</sub>S on the uptake of [<sup>125</sup>I]T<sub>3</sub> by pituitary cells was dose-dependent, and was still lower (34% inhibition) when T<sub>3</sub>S was added at a concentration of 1 μmol/L as compared with the effect of 10 nmol/L T<sub>3</sub> (40% inhibition). In our previous study,<sup>11</sup> it was observed that addition of 1 nmol/L T<sub>3</sub> reduced the uptake of [<sup>125</sup>I]T<sub>3</sub> by approximately 29%. Thus, the effects of T<sub>3</sub>S on [<sup>125</sup>I]T<sub>3</sub> uptake are also compatible with a contamination of the T<sub>3</sub>S preparation with T<sub>3</sub> (<1%). Our results are also in line with those of Spaulding et al,<sup>8</sup> who apparently used more purified T<sub>3</sub>S and found no displacement of [<sup>125</sup>I]T<sub>3</sub> from the nuclear receptors in the growth hormone-producing cell line GH<sub>4</sub>C<sub>1</sub> in the concentration range of 0.001 to 1 μmol/L T<sub>3</sub>S.

The explanation that the effect of high concentrations of T<sub>3</sub>S on TRH-induced TSH secretion or [<sup>125</sup>I]T<sub>3</sub> uptake is due to contamination of the T<sub>3</sub>S preparation with T<sub>3</sub> is also supported by our observation that [<sup>125</sup>I]T<sub>3</sub>S itself was only poorly taken up by the pituitary cells. This was concluded from a series of experiments where a significant amount of [<sup>125</sup>I]T<sub>3</sub>, added at the same radioactive and molar concentration as [<sup>125</sup>I]T<sub>3</sub>S, was taken up by the pituitary cells. In contrast, both [<sup>125</sup>I]T<sub>3</sub> and [<sup>125</sup>I]T<sub>3</sub>S were taken up by hepatocytes, although the uptake of [<sup>125</sup>I]T<sub>3</sub> was roughly fourfold higher than that of [<sup>125</sup>I]T<sub>3</sub>S. On the other hand, despite this difference in uptake, iodide production from [<sup>125</sup>I]T<sub>3</sub>S was at least as high as that from [<sup>125</sup>I]T<sub>3</sub>. This indicated that T<sub>3</sub>S and T<sub>3</sub> (after preceding sulfation<sup>19</sup>) were deiodinated followed by efflux of <sup>125</sup>I<sup>-</sup> from the liver cells. These results also confirmed the previous observation that

T<sub>3</sub>S is a preferred substrate for the liver type I deiodinase, being deiodinated successively in the inner and outer ring.<sup>12,19</sup> During the 2 hours of the experiments, no unconjugated T<sub>3</sub> was detectable in the media from hepatocytes incubated with [<sup>125</sup>I]T<sub>3</sub>S. This seems to be in contrast to the observations of Kung et al,<sup>20</sup> who reported 1% hydrolysis of T<sub>3</sub>S per hour in isolated hepatocytes. The reason for this discrepancy might be that hepatocytes were incubated in the presence of T<sub>3</sub>S in the micromolar range (7 to 50 μmol/L) in the study by Kung et al,<sup>20</sup> which is far above the *K<sub>m</sub>* of the type I deiodinase for T<sub>3</sub>S (4.6 μmol/L<sup>21</sup>), resulting in saturation of the deiodination pathway. In our experiments, the T<sub>3</sub>S concentration was in the picomolar range.

Although the anterior pituitary is generally regarded as an organ with a low type I deiodinase activity,<sup>22</sup> extremely rapid deiodination of [<sup>125</sup>I]T<sub>3</sub>S and efflux of <sup>125</sup>I<sup>-</sup> could theoretically account for the observation that cellular uptake of [<sup>125</sup>I]T<sub>3</sub>S was hardly detectable. It was recently reported that the posterior pituitary,<sup>23</sup> like the brain,<sup>24</sup> contains type III deiodinase that would deiodinate T<sub>3</sub>. This

reaction would only be detectable by <sup>125</sup>I<sup>-</sup> production, if the inner-ring deiodination by type III deiodinase is followed by outer-ring deiodination. Furthermore, T<sub>3</sub>S is not a substrate for the type III deiodinase.<sup>25</sup> The LH-20 chromatography performed in the same way as for the hepatocyte experiments showed no <sup>125</sup>I<sup>-</sup> production from [<sup>125</sup>I]T<sub>3</sub>S or from [<sup>125</sup>I]T<sub>3</sub> during the hour the experiment lasted.

Taken together, our results strongly suggest that relative to T<sub>3</sub>, T<sub>3</sub>S is poorly taken up by the pituitary gland. In addition, it seems that T<sub>3</sub>S is not hydrolyzed in this tissue, and consequently the biological effects of T<sub>3</sub>S on the euthyroid pituitary gland are minimal.

#### ACKNOWLEDGMENT

The material used in the TSH assay was kindly provided by the National Hormone and Pituitary Program of the National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, MD). We thank H. van Toor, H.F. Bernard, E.P.C.M. Moerings, and A.M.P. Tempelaars for skillful technical assistance.

#### REFERENCES

1. Roche J, Michel R: On the peripheral metabolism of thyroid hormones. *Ann NY Acad Sci* 86:454-468, 1960
2. Roche J, Michel R, Closon J, et al: Sur le métabolisme du sulfoconjugué de la 3,5,3'-triiodothyronine chez le rat. *Biochim Biophys Acta* 38:325-332, 1960
3. Visser TJ, van Buuren J, Rutgers M, et al: The role of sulfation in thyroid hormone metabolism. *Trends Endocrinol Metab* 1:211-218, 1990
4. Vagenakis AG, Burger A, Portnay GI, et al: Diversion of peripheral thyroxine metabolism from activating to inactivating pathways during complete fasting. *J Clin Endocrinol Metab* 41:191-194, 1975
5. Spencer CA, Lum SMC, Wilber JF, et al: Dynamics of serum thyrotropin and thyroid hormone changes in fasting. *J Clin Endocrinol Metab* 56:883-888, 1983
6. Chopra IJ, Wu S-Y, Chua Teco GN, et al: A radioimmunoassay for measurement of 3,5,3'-triiodothyronine sulfate: Studies in thyroidal and non-thyroidal diseases, pregnancy and neonatal life. *J Clin Endocrinol Metab* 75:189-194, 1992
7. LoPresti JS, Mizuno L, Nimalysuria A, et al: Characteristics of 3,5,3'-triiodothyronine sulfate metabolism in euthyroid man. *J Clin Endocrinol Metab* 73:703-709, 1991
8. Spaulding SW, Smith TJ, Hinkle PM, et al: Studies on the biological activity of triiodothyronine sulfate. *J Clin Endocrinol Metab* 74:1062-1067, 1992
9. Santini F, Chopra IJ, Wu S-Y, et al: Metabolism of 3,5,3'-triiodothyronine sulfate by tissues of the fetal rat: A consideration of the role of desulfation of 3,5,3'-triiodothyronine sulfate as a source of T<sub>3</sub>. *Pediatr Res* 31:541-544, 1992
10. Santini F, Hurd RE, Lee B, et al: Thyromimetic effects of 3,5,3'-triiodothyronine sulfate in hypothyroid rats. *Endocrinology* 133:105-110, 1993
11. Everts ME, Docter R, van Buuren J, et al: Evidence for carrier-mediated uptake of triiodothyronine in cultured anterior pituitary cells. *Endocrinology* 132:1278-1285, 1993
12. Eelkman Rooda SJ, Otten MH, van Loon MAC, et al: Metabolism of triiodothyronine in rat hepatocytes. *Endocrinology* 125:2187-2197, 1989
13. Oosterom R, Verleun T, Lamberts SWJ: Basal and dopamine-inhibited prolactin secretion by anterior pituitary cells: Effects of culture conditions. *Mol Cell Endocrinol* 29:197-212, 1983
14. Oosterom R, Verleun T, Zuyderwijk J, et al: Growth hormone secretion by cultured rat anterior pituitary cells. Effects of culture conditions and dexamethasone. *Endocrinology* 113:735-741, 1983
15. Krenning EP, Docter R, Bernard HF, et al: Active transport of triiodothyronine (T<sub>3</sub>) into isolated liver cells. *FEBS Lett* 91:113-116, 1978
16. Docter R, Krenning EP, Bernard HF, et al: Inhibition of uptake of thyroid hormone into rat hepatocytes by preincubation with *N*-bromoacetyl-3-3',5 triiodothyronine. *Endocrinology* 123:1520-1525, 1988
17. Sterling K, Brenner MA: Free thyroxine in human serum: Simplified measurement with the aid of magnesium precipitation. *J Clin Invest* 45:153-163, 1966
18. Mol JA, Visser TJ: Synthesis and some properties of sulfate esters and sulfamates of iodothyronines. *Endocrinology* 117:1-7, 1985
19. Otten MH, Mol JA, Visser TJ: Sulfation preceding deiodination of iodothyronines in rat hepatocytes. *Science* 221:81-84, 1983
20. Kung M-P, Spaulding SW, Roth JA: Desulfation of 3,5,3'-triiodothyronine sulfate by microsomes from human and rat tissues. *Endocrinology* 122:1195-1200, 1988
21. Visser TJ, Mol JA, Otten MH: Rapid deiodination of triiodothyronine sulfate by rat liver microsomal fraction. *Endocrinology* 112:1547-1549, 1983
22. Köhrle J, Hesch RD, Leonard JL: Intracellular pathways of iodothyronine metabolism, in Braverman LE, Utiger RD (eds): *The Thyroid* (ed 6). Philadelphia, PA, Lippincott, 1991, pp 144-189
23. Tanaka K, Shimatsu A, Imura H: Iodothyronine 5-deiodinase in rat posterior pituitary. *Biochem Biophys Res Commun* 188:272-277, 1992
24. Visser TJ, Schoenmakers CHH: Characteristics of type III iodothyronine deiodinase. *Acta Med Austriaca* 19:18-21, 1992
25. Santini F, Hurd RE, Chopra IJ: A study of metabolism of deaminated and sulfoconjugated iodothyronines by rat placental iodothyronine 5-monodeiodinase. *Endocrinology* 131:1689-1694, 1992